This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Alprazolam, Carbamazepine, Trifluoperazine, and Tranylcypromine

Rex William Cowdry, MD; David L. Gardner, MD

Arch Gen Psychiatry. 1988;45(2):111-119.

Abstract
• Sixteen female outpatients with borderline personality disorder and prominent behavioral dyscontrol, but without a current episode of major depression, were studied in a doubleblind, crossover trial of placebo and the following four active medications: alprazolam (average dose, 4.7 mg/d); carbamazepine (average dose, 820 mg/d); trifluoperazine hydrochloride (average dose, 7.8 mg/d); and tranylcypromine sulfate (average dose, 40 mg/d). Each trial was designed to last six weeks. Tranylcypromine and carbamazepine trials had the highest completion rates. Physicians rated patients as significantly improved relative to placebo while receiving tranylcypromine and carbamazepine. Patients rated themselves as significantly improved relative to placebo only while receiving tranylcypromine. Patients who tolerated a full trial of trifluoperazine showed improvement, those receiving carbamazepine demonstrated a marked decrease in the severity of behavioral dyscontrol, and those receiving alprazolam had an increase in the severity of the episodes of serious dyscontrol. As an adjunct to psychotherapy, pharmacotherapy can produce modest but clinically important improvement in the mood and behavior of patients with borderline personality disorder. As a research tool, patterns of pharmacological response may provide clues to biological mechanisms underlying dysphoria and behavioral dyscontrol.

Author Affiliations
From the Intramural Research Program, National Institute of Mental Health, Bethesda, Md.

Footnotes
Accepted for publication March 5, 1987.

Reprint requests to the Office of the Clinical Director, National Institute of Mental Health, The Clinical Center 10/3N238, Bethesda, MD 20892 (Dr Cowdry).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Borderline Personality Disorder: Ontogeny of a Diagnosis
Gunderson
Am. J. Psychiatry 2009;166:530-539.
ABSTRACT | FULL TEXT  

Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study
Schulz et al.
Br. J. Psychiatry 2008;193:485-492.
ABSTRACT | FULL TEXT  

Systems Training for Emotional Predictability and Problem Solving (STEPPS) for Outpatients With Borderline Personality Disorder: A Randomized Controlled Trial and 1-Year Follow-Up
Blum et al.
Am. J. Psychiatry 2008;165:468-478.
ABSTRACT | FULL TEXT  

References
APPI Online CME 2007;2007:2-2.
FULL TEXT  

Borderline personality disorder
Paris
CMAJ 2005;172:1579-1583.
ABSTRACT | FULL TEXT  

Drug treatment for personality disorders
Tyrer and Bateman
Adv. Psychiatr. Treat. 2004;10:389-398.
ABSTRACT | FULL TEXT  

Electrophysiological Aberrations in Borderline Personality Disorder: State of the Evidence
Boutros et al.
J. Neuropsychiatry Clin. Neurosi. 2003;15:145-154.
ABSTRACT | FULL TEXT  

Do antidepressants have any potential to cause addiction?
Haddad
J Psychopharmacol 1999;13:300-307.
ABSTRACT  

Fluoxetine and Impulsive Aggressive Behavior in Personality-Disordered Subjects
Coccaro and Kavoussi
Arch Gen Psychiatry 1997;54:1081-1088.
ABSTRACT  

Manual-Guided Psychosocial Treatment: A New Virtual Requirement for Pharmacotherapy Trials?
Carroll
Arch Gen Psychiatry 1997;54:923-928.
ABSTRACT  

Efficacy of Phenelzine and Haloperidol in Borderline Personality Disorder
Soloff et al.
Arch Gen Psychiatry 1993;50:377-385.
ABSTRACT  

Intentional Self-injection With HIV
El-Mallakh
JAMA 1992;268:1541-1541.
ABSTRACT  

Cognitive-Behavioral Treatment of Chronically Parasuicidal Borderline Patients
Linehan et al.
Arch Gen Psychiatry 1991;48:1060-1064.
ABSTRACT  

Effects of Carbamazepine on Dopamine- and Serotonin-Mediated Neuroendocrine Responses
Elphick et al.
Arch Gen Psychiatry 1990;47:135-140.
ABSTRACT  

The psychopharmacological era: notes toward a history
Healy
J Psychopharmacol 1990;4:152-167.
ABSTRACT